KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Tax Provisions (2016 - 2025)

Biogen has reported Tax Provisions over the past 17 years, most recently at -$7.1 million for Q4 2025.

  • Quarterly results put Tax Provisions at -$7.1 million for Q4 2025, down 128.63% from a year ago — trailing twelve months through Dec 2025 was $263.6 million (down 3.73% YoY), and the annual figure for FY2025 was $263.6 million, down 3.73%.
  • Tax Provisions for Q4 2025 was -$7.1 million at Biogen, down from $90.8 million in the prior quarter.
  • Over the last five years, Tax Provisions for BIIB hit a ceiling of $443.2 million in Q4 2021 and a floor of -$409.1 million in Q2 2021.
  • Median Tax Provisions over the past 5 years was $66.6 million (2024), compared with a mean of $67.9 million.
  • Peak annual rise in Tax Provisions hit 3232.33% in 2021, while the deepest fall reached 191.71% in 2021.
  • Biogen's Tax Provisions stood at $443.2 million in 2021, then plummeted by 87.75% to $54.3 million in 2022, then decreased by 21.36% to $42.7 million in 2023, then tumbled by 41.92% to $24.8 million in 2024, then tumbled by 128.63% to -$7.1 million in 2025.
  • The last three reported values for Tax Provisions were -$7.1 million (Q4 2025), $90.8 million (Q3 2025), and $109.2 million (Q2 2025) per Business Quant data.